2/11
07:00 am
hind
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
Medium
Report
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
2/2
07:00 am
hind
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
High
Report
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
1/27
08:00 am
hind
Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study
High
Report
Independent Analyst Values Vyome’s VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study
12/30
04:16 pm
hind
Vyome (NASDAQ:HIND) had its "sell (e-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Vyome (NASDAQ:HIND) had its "sell (e-)" rating reaffirmed by analysts at
Weiss Ratings.
12/29
06:37 am
hind
We're Not Very Worried About Vyome Holdings' (NASDAQ:HIND) Cash Burn Rate [Yahoo! Finance]
Medium
Report
We're Not Very Worried About Vyome Holdings' (NASDAQ:HIND) Cash Burn Rate [Yahoo! Finance]
12/23
04:14 pm
hind
Vyome (NASDAQ:HIND) had its "sell (e-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Vyome (NASDAQ:HIND) had its "sell (e-)" rating reaffirmed by analysts at
Weiss Ratings.
12/22
08:00 am
hind
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company
Medium
Report
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company
12/17
04:39 pm
hind
Vyome (NASDAQ:HIND) had its "sell (e-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Vyome (NASDAQ:HIND) had its "sell (e-)" rating reaffirmed by analysts at
Weiss Ratings.
12/11
04:24 pm
hind
Vyome (NASDAQ:HIND) had its "sell (e-)" rating reaffirmed by analysts at
Weiss Ratings.
Medium
Report
Vyome (NASDAQ:HIND) had its "sell (e-)" rating reaffirmed by analysts at
Weiss Ratings.
12/8
08:00 am
hind
Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval
Medium
Report
Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval
12/5
04:29 pm
hind
Vyome (NASDAQ:HIND) had its "sell (e-)" rating reaffirmed by analysts at
Weiss Ratings.
High
Report
Vyome (NASDAQ:HIND) had its "sell (e-)" rating reaffirmed by analysts at
Weiss Ratings.
11/29
03:39 pm
hind
Vyome (NASDAQ:HIND) had its "sell (e-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Vyome (NASDAQ:HIND) had its "sell (e-)" rating reaffirmed by analysts at
Weiss Ratings.
11/25
07:46 am
hind
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program [Yahoo! Finance]
Low
Report
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program [Yahoo! Finance]
11/25
07:00 am
hind
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program
Low
Report
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program
11/24
01:56 pm
hind
Vyome (NASDAQ:HIND) is now covered by analysts at
Weiss Ratings. They set a "sell (e-)" rating on the stock.
Neutral
Report
Vyome (NASDAQ:HIND) is now covered by analysts at
Weiss Ratings. They set a "sell (e-)" rating on the stock.
11/18
07:46 am
hind
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing [Yahoo! Finance]
Low
Report
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing [Yahoo! Finance]
11/18
07:00 am
hind
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
Medium
Report
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing